You are here

hemophilia A

Sigilon Therapeutics approaches the clinic

Sigilon Therapeutics approaches the clinic

EP Vantage

Flag link:

BioMarin talks down worries on gene therapy data differences

BioMarin talks down worries on gene therapy data differences

Biopharma Dive

Flag link:

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

valoctocogene roxaparvovec

Flag link:

Bayer recalls mislabeled vials of hemophilia A treatment

Bayer recalls mislabeled vials of hemophilia A treatment

Fierce Pharma

product recalls

Flag link:

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Billions on the line: BioMarin bustles past enthused rival, planning to launch world’s first hemophilia A gene therapy

Endpoints

Flag link:

Sangamo backs up early success for hemophilia gene therapy

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Spark Therapeutics

Flag link:

How BioMarin May Revolutionize the Hemophilia Treatment Market

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Flag link:

Does Sangamo Have the Best Gene Therapy Program Now?

Does Sangamo Have the Best Gene Therapy Program Now?

Motley Fool

Sangamo Therapeutics

Flag link:

FDA Approves Roche Drug For All Hemophilia A Patients, But Rivals Loom

FDA Approves Roche Drug For All Hemophilia A Patients, But Rivals Loom

Xconomy

Flag link:

Roche reveals haemophilia drug data ahead of label expansion decision

Roche reveals haemophilia drug data ahead of label expansion decision

Pharmaforum

Flag link:

Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi

Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi

BioSpace

Flag link:

Spark’s gene therapy data answer some burning questions — and raise a few more

Spark’s gene therapy data answer some burning questions — and raise a few more

Stat

Spark Therapeutcs

Flag link:

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Endpoints

Flag link:

Roche drug dramatically reduces bleeds in key hemophilia tests

Roche drug dramatically reduces bleeds in key hemophilia tests

Reuters

clinical trials

Flag link:

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

ASH17: Spark gene therapy falls behind BioMarin in hemophilia

BioPharma Dive

Spark Therapeutics

Flag link:

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia

BioPharma Dive

Flag link:

FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning

FDA Approves Genentech Hemophilia Drug, But Adds Safety Warning

Xconomy

Flag link:

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

Endpoints

Flag link:

Bayer files longer-acting bleeding candidate to FDA

Bayer files longer-acting bleeding candidate to FDA

Fierce Biotech

Flag link:

Pages